Helminth exposure and immune response to the two-dose heterologous Ad26.ZEBOV, MVA-BN-Filo Ebola vaccine regimen.

MLA

Barry, Houreratou, et al. “Helminth Exposure and Immune Response to the Two-Dose Heterologous Ad26.ZEBOV, MVA-BN-Filo Ebola Vaccine Regimen.” PLoS Neglected Tropical Diseases, vol. 18, no. 4, Apr. 2024, pp. 1–16. EBSCOhost, https://doi.org/10.1371/journal.pntd.0011500.

APA

Barry, H., Lhomme, E., Surénaud, M., Nouctara, M., Robinson, C., Bockstal, V., Valea, I., Somda, S., Tinto, H., Meda, N., Greenwood, B., Thiébaut, R., & Lacabaratz, C. (2024). Helminth exposure and immune response to the two-dose heterologous Ad26.ZEBOV, MVA-BN-Filo Ebola vaccine regimen. PLoS Neglected Tropical Diseases, 18(4), 1–16. https://doi.org/10.1371/journal.pntd.0011500

Chicago

Barry, Houreratou, Edouard Lhomme, Mathieu Surénaud, Moumini Nouctara, Cynthia Robinson, Viki Bockstal, Innocent Valea, et al. 2024. “Helminth Exposure and Immune Response to the Two-Dose Heterologous Ad26.ZEBOV, MVA-BN-Filo Ebola Vaccine Regimen.” PLoS Neglected Tropical Diseases 18 (4): 1–16. doi:10.1371/journal.pntd.0011500.